Osteoporosis - Drug Pipeline Analysis and Market Forecasts to 2016

The Osteoporosis Therapeutics Market is Forecast to Show Significant Growth to 2016

The global osteoporosis therapeutics market was valued at $9.6 billion in 2009. It is
expected to grow to $16.7 billion at a compound annual growth rate (CAGR) of 8.2% by
2016. This significant growth is primarily attributed to strong current treatment options
as well as strong pipeline candidates. The increase in the prevalence of osteoporosis
among the female population is the principal driver of the osteoporosis market and will
continue to be in the future. The significant reason for the increase in prevalence is due
to the decline in the use of hormone replacement therapy (HRT) in healthy
postmenopausal women. HRT has been used to help prevent the bone loss that leads to
osteoporosis. However, recent negative study results, showing the increased risk of
heart attack, stroke, breast cancer and blood clots, have led to a decline in HRT usage.
Therefore, population growth and the increase in the prevalent population will combine
to contribute to the increased burden of osteoporosis.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoporosis-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_H
ealthcare

Current Treatment Options are Moderately Successful in Meeting Market Demand

GlobalData has analyzed the current market landscape and found it to be strong.
Antiresorptive and bone-forming drugs are the two main types of drugs which are used
in the treatment of osteoporosis. Bisphosphonates, calcitonin, estrogen and estrogen
agonists/antagonists are the major antiresorptive drugs available in the market. They
include alendronate (Fosamax), risedronate (Actonel), ibandronate (Bonivia), zoledronic
acid (Reclast) and raloxifene (Evista). The market is currently dominated by
antiresorptive drugs. However, bone-building drugs are being developed by researchers
and are just becoming available. Eli Lilly is the only company which has two products –
Evista and Forteo in the osteoporosis market. Neither of these drugs are part of the
bisphosphonate class. Forteo is the first and the only bone-forming drug available in the
market.

Poor Diagnosis of the Disease is a Major Barrier for the Osteoporosis Market

The poor diagnosis of the disease is a major barrier for the osteoporosis market. One of
the major reasons why osteoporosis is underdiagnosed is that most vertebral fractures
are asymptomatic and therefore go unrecognized by the patient and physician. Even
patients with clinically apparent fragility fractures are overlooked, with fewer than 5% of
patients with osteoporotic fractures being referred for medical evaluation and
treatment. The large majority of patients with fragility fractures are not referred for
further evaluation and treatment. Studies have shown that older women and men with
hip fractures do not receive follow-up drug treatment.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoporosis-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_H
ealthcare

Strong Pipeline Candidates are Expected to Intensify Future Competition

GlobalData found that there are more than 130 products in different stages of
development. Most of the products in clinical development are me-too. These products
are a mixture of calcium modulators, cathepsin K (CTSK) inhibitor, bone-tissue
resorption inhibitors and selective estrogen receptors modulators (SERM). If successfully
launched, these products are expected to meet patients’ expectations. It may also lead
to an intensely competitive market landscape and the existing market leaders will have
to be prepared to manage this dynamic, yet challenging, scenario. The largest growth
driver of the osteoporosis market is expected to be Amgen’s Prolia (denosumab), which
is the first monoclonal antibody on the market.

GlobalData, the industry analysis specialist, has released its latest research,
“Osteoporosis - Drug Pipeline Analysis and Market Forecasts to 2016” which provides
key data, information and analysis on the osteoporosis market. The report provides a
comprehensive overview of the annualized market data from 2001 to 2009, and
forecasts forward seven years to 2016. The research also includes market
characterization, opportunities, the unmet needs associated with osteoporosis,
competitive assessment, product profiles of major marketed products and promising
drugs in the pipeline, an overview on discontinued projects, implications for future
market competition, and the key players of the osteoporosis market.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Osteoporosis-Drug-Pipeline-
Analysis-and-Market-Forecasts-to-
2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_H
ealthcare

Or visit our report store: http://www.globaldata.com/reportstore

Contact Information:
Rajesh Gunnam
rgunnam@globaldata.com
+914066166782